EG — Everest Group, Ltd.

The tape is neutral-to-mildly-constructive but lacks conviction. As of 2026-09-13 the stock was up 16.0% over six months and 9.5% over three months, yet it slipped 2.4% in the last week and sat 0.5% below its 20-day and 0.7% below its 50-day SMA. Fundamentals cut both ways: Q2 2026 (reported July 29, 2026) operating EPS of $14.85 beat the $14.52 consensus, but revenue fell 11.8% YoY to $3.96B and gross written premium dropped 19.4% to $3.77B, with the combined ratio deteriorating 300bps to 90%. Sell-side consensus is an outright "Hold" (8 buy, 14 hold, 0 sell) with a $402.25 average target, and the story is being re-shaped by portfolio pruning (Mexico insurance operations to Fairfax on Aug 5, 2026; Colombia to AIG on May 19, 2026) and the June 2026 Stone Point casualty sidecar Annapurna Re Ltd. Institutional 13F stake-building by BlackRock, Barrow Hanley and William Blair offsets the soft top line, but nobody is paying up for the shares.

Revenue has clearly decelerated and now is contracting: quarterly revenue peaked at $4.61B in Q4 2024 and ran $4.24B/$4.40B/$4.25B/$4.42B through 2025 before dropping to $4.07B in Q1 2026 and $3.96B in Q2 2026. YoY growth went +0.1% (Q3 2025), -4.2% (Q4 2025), -4.0% (Q1 2026), -10.1% (Q2 2026) - this is not a one-quarter blip, it is a progressively steepening decline driven by soft reinsurance pricing plus deliberate exits from non-core retail books. Earnings, by contrast, have inflected upward from a catastrophically weak stretch: diluted EPS went -$13.80 (Q4 2024, a -$593M net loss quarter from cat losses), $4.90 (Q1 2025), $16.10 (Q2 2025), $6.09 (Q3 2025), $10.77 (Q4 2025), $16.21 (Q1 2026) and $13.88 (Q2 2026). TTM EPS of $47.49 is a big recovery off FY2025's ~$37.86, and H1 2026 EPS of $30.09 already exceeds the entire 2025 total. The split diagnosis: earnings recovery is real but cat-exposed and lumpy; the premium contraction is cyclical/price-driven and partly self-inflicted via discipline, not a loss of franchise. TTM operating cash flow, however, halved YoY from roughly $4.5B to ~$2.1B, which is real - though insurance OCF swings violently with loss-payment and reserve timing (Q4 2025 OCF was -$330M versus +$1.46B in Q3 2025). Operating margin (TTM) is 15.4%, net margin 11.5%, ROE 10.3%, ROIC 8.1%.

Cheap, against both its own history and the market. As of 2026-09-13, the shares trade at 7.9x TTM EPS of $47.49 versus a 5-year average P/E of 11.19x - a ~29% discount - and at just 6.9x the $53.54 forward consensus EPS. P/B is 0.97x on ~$390/share of book value, P/S is 0.88 versus a 5-year average of 0.95, EV/EBITDA is 6.6x, and the dividend yield is 2.18% on a $2.00 quarterly payout. A discount is warranted given negative premium growth and a softening cycle, but 0.95x book for a business still earning a 10.3% ROE and printing a 90% combined ratio looks like more punishment than the fundamentals justify. The PEG of 0.054 is a statistical artifact of low reported growth and should not be leaned on.

The setup is a classic mismatch: the multiple (6.9x forward) prices in a continued earnings decline that the estimates themselves do not show - FY2026-FY2028 EPS estimates have been revised UP (Zacks-type revisions cited in the brief), and Q2 2026 beat on the bottom line. So the market is discounting forward deterioration while the sell side is modeling improvement. The catch is timing: written premium leads earned premium by roughly 4-8 quarters, so the -19.4% Q2 gross written premium decline will keep bleeding into earned revenue well into 2027 even if pricing stabilizes at the 1/1/2027 renewals. Read the stock as "underpricing a stable-margin, shrinking-volume franchise" rather than "pricing in growth that hasn't shown up." The re-rating trigger is evidence that rate declines are bottoming - not another EPS beat.

As of 2026-09-13, RSI(14) stood at 48.38 - squarely neutral, no oversold or overbought signal. The price of $371.71 was 0.5% below the 20-day SMA and 0.71% below the 50-day, but 8.06% above the 200-day, which is the profile of a mild pullback inside an intact uptrend rather than a breakdown. Returns: -2.41% over one week, +2.21% over one month, +9.52% over three months, +16.03% over six months, with a 52-week range of $302.44-$401.07. The stock is consolidating in roughly the $360-$400 band. Entry-timing implication: there is no urgency here - a move back above the 20/50-day would confirm the trend, while a break below the 200-day (roughly the mid-$340s, drifting higher) would be the first real warning. For a value buyer, the current consolidation is a reasonable accumulation zone, but it is not a capitulation price.

• Soft reinsurance pricing cycle: abundant industry capital and heightened competition are pushing rate-on-line down, which is the direct cause of the -19.4% YoY gross written premium decline and the core threat to 2027 earned premium.
• Social inflation in US casualty: rising litigation costs and larger jury awards continue to threaten reserve adequacy on long-tail liabilities, the single biggest balance-sheet risk for a casualty-heavy reinsurer.
• Catastrophe frequency/severity: the North Atlantic hurricane season peaks Aug-Oct, and a single bad quarter can erase a year of underwriting profit (Q4 2024 produced a -$593M net loss and -$13.80 EPS).
• Interest rates and investment returns: net investment income of $523M in Q2 2026 fell 1.7% YoY on softer alternative-investment returns; reinvestment yields and alt-asset marks now drive an outsized share of earnings as underwriting profit compresses.
• Third-party capital / ILS proliferation: the Annapurna Re sidecar (with Stone Point, June 2026) adds fee income and capital flexibility but is also emblematic of the excess capital supply that keeps pressuring reinsurance pricing.

• Q3 2026 earnings (expected late Oct/early Nov 2026): the key reads are catastrophe losses versus budget, whether the combined ratio holds near 90%, and any sign that premium volume is stabilizing.
• January 1, 2027 reinsurance renewals: management commentary in Q3/Q4 2026 on property-cat pricing floors and margin sustainability will set expectations for the whole of 2027 - this is the single most important variable for the multiple.
• Continued portfolio optimization and capital return: completion of the Mexico (Fairfax) and Colombia (AIG) sales, further pruning of non-core retail, and the possibility of stepped-up buybacks given the shares trade below book value.
• Reserve development disclosures on casualty lines - positive development would validate the conservative reserve posture, adverse development would crack the thesis.

• A persistently softening reinsurance market drives earned premium - and eventually EPS - lower in 2027, forcing the Street's upward-revised estimates to be cut and keeping the multiple pinned in the high-single digits.
• Adverse casualty reserve development from social inflation, which would hit book value and undermine the 0.97x P/B 'cheapness' argument directly.
• Catastrophe losses above budget during the live hurricane season, repeating the Q4 2024 pattern of a single quarter swinging earnings sharply negative.
• Cash generation has deteriorated materially - TTM operating cash flow fell from roughly $4.5B to ~$2.1B - which, if not purely reserve/cat timing, would constrain dividends and buybacks.
• Mediocre absolute returns: ROE of 10.3% and ROIC of 8.1% leave little margin for error; if ROE drifts toward high single digits, trading below book is deserved rather than opportunistic.

Everest is a genuinely cheap, well-capitalized global reinsurer trading at 0.95x book and ~6.9x forward earnings with a 2.2% dividend - roughly a 30% discount to its own five-year average P/E - at a moment when trailing revenue and cash flow look ugly because reinsurance pricing is softening and the company is deliberately shrinking its non-core retail footprint. Earnings are still beating (Q2 2026 operating EPS $14.85 versus $14.52 consensus) and forward estimates are being revised up, which says the earnings power is durable even as the top line contracts. The honest problem is that there is no near-term catalyst to force a re-rating while rate declines continue and hurricane season is live, so this is a 'cheap for a reason' watchlist name: the valuation is compelling enough to own on evidence that the 1/1/2027 renewals are firming, but buying today means being early and absorbing cycle risk with no margin of safety from the tape.

I blended two anchors. First, 7.8x forward consensus EPS of $53.54 = $418 - a multiple justified as a ~30% discount to the 5-year average trailing P/E of 11.19x (reflecting the softening pricing cycle and negative premium growth) but well above the current 6.9x, which embeds peak-cycle pessimism. Second, 1.05x book value: equity of $15.43B over ~39.6M shares gives BVPS of ~$390, and a 10.3% TTM ROE with a 2.2% dividend and a 90% combined ratio supports trading at least modestly above book, = ~$410. Weighting the two roughly evenly gives ~$414, about 11% above the 2026-09-13 price of $371.71 and just above the $402.25 analyst consensus.